OBJECTIVES: Delaying nephrectomy<3 months does not adversely affect treatment outcome of renal tumors. Whether surgical waiting time (SWT; time from diagnosis to surgery)>3 months affects treatment outcome for large renal masses has not been well studied. We aimed to evaluate if SWT is associated with treatment outcome of renal masses >4cm and identify patients who are more likely to experience prolonged SWT. MATERIALS AND METHODS: Data from 1,484 patients undergoing radical or partial nephrectomy at a single institution for a nonmetastatic renal mass>4cm between 1995 and 2013 were reviewed. Patients with benign tumors and incomplete preoperative data were excluded. The association between SWT and disease upstaging at the time of surgery and recurrence at 2 and 5 years was assessed using logistic regression. Cancer-specific survival (CSS) and overall survival were assessed with landmark survival analyses and multivariable Cox proportional hazards models. All analyses were adjusted for patient and tumor characteristics. RESULTS: Of the final cohort of 1,278 patients, 267 (21%) had SWT>3 months. Patients with larger, symptomatic tumors had shorter SWT. Median follow-up for survivors was 3.8 years (interquartile range: 1.5-7.4). On multivariable analysis, SWT was not associated with disease upstaging, recurrence, or CSS. Longer SWT was associated with decreased overall survival (hazard ratio = 1.17; 95% CI: 1.08-1.27; P = 0.0002). Sex and tumor size, histology, and presentation were associated with disease upstaging, recurrence, and CSS. The most common cause for surgical delay>3 months was evaluation and treatment of comorbidities. CONCLUSION: Patient and tumor characteristics, rather than SWT, were associated with disease upstaging, recurrence, and CSS, and should guide the decision to delay surgery when treating nonmetastatic renal tumors>4cm.
OBJECTIVES: Delaying nephrectomy<3 months does not adversely affect treatment outcome of renal tumors. Whether surgical waiting time (SWT; time from diagnosis to surgery)>3 months affects treatment outcome for large renal masses has not been well studied. We aimed to evaluate if SWT is associated with treatment outcome of renal masses >4cm and identify patients who are more likely to experience prolonged SWT. MATERIALS AND METHODS: Data from 1,484 patients undergoing radical or partial nephrectomy at a single institution for a nonmetastatic renal mass>4cm between 1995 and 2013 were reviewed. Patients with benign tumors and incomplete preoperative data were excluded. The association between SWT and disease upstaging at the time of surgery and recurrence at 2 and 5 years was assessed using logistic regression. Cancer-specific survival (CSS) and overall survival were assessed with landmark survival analyses and multivariable Cox proportional hazards models. All analyses were adjusted for patient and tumor characteristics. RESULTS: Of the final cohort of 1,278 patients, 267 (21%) had SWT>3 months. Patients with larger, symptomatic tumors had shorter SWT. Median follow-up for survivors was 3.8 years (interquartile range: 1.5-7.4). On multivariable analysis, SWT was not associated with disease upstaging, recurrence, or CSS. Longer SWT was associated with decreased overall survival (hazard ratio = 1.17; 95% CI: 1.08-1.27; P = 0.0002). Sex and tumor size, histology, and presentation were associated with disease upstaging, recurrence, and CSS. The most common cause for surgical delay>3 months was evaluation and treatment of comorbidities. CONCLUSION:Patient and tumor characteristics, rather than SWT, were associated with disease upstaging, recurrence, and CSS, and should guide the decision to delay surgery when treating nonmetastatic renal tumors>4cm.
Authors: Michael Jewett; Ricardo Rendon; George Dranitsaris; Darrel Drachenberg; Simon Tanguay; Bryan Donnelly; Neil Fleshner Journal: Can J Urol Date: 2006-06 Impact factor: 1.344
Authors: Ross J Mason; Mohamed Abdolell; Greg Trottier; Christopher Pringle; Joseph G Lawen; David G Bell; Michael A S Jewett; Laurence Klotz; Ricardo A Rendon Journal: Eur Urol Date: 2011-02-22 Impact factor: 20.096
Authors: Kwang Hyun Kim; Dalsan You; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2012-05-01 Impact factor: 4.553
Authors: Carlos H Martínez; Paul Martin; Venu Chalasani; Andrew K Williams; Patrick P W Luke; Jonathan I Izawa; Joseph L Chin; Larry Stitt; Stephen E Pautler Journal: Can Urol Assoc J Date: 2011-03-01 Impact factor: 1.862
Authors: Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2012-06-13 Impact factor: 7.450
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: Soroush Rais-Bahrami; Thomas J Guzzo; Thomas W Jarrett; Louis R Kavoussi; Mohamad E Allaf Journal: BJU Int Date: 2009-02-23 Impact factor: 5.588
Authors: Michael Staehler; Nicolas Haseke; Thomas Stadler; Ekaterina Zilinberg; Cordula Nordhaus; Philip Nuhn; Wael Y Khoder; Alexander Karl; Christian G Stief Journal: BJU Int Date: 2009-09-14 Impact factor: 5.588
Authors: Amit Sud; Bethany Torr; Michael E Jones; John Broggio; Stephen Scott; Chey Loveday; Alice Garrett; Firza Gronthoud; David L Nicol; Shaman Jhanji; Stephen A Boyce; Matthew Williams; Elio Riboli; David C Muller; Emma Kipps; James Larkin; Neal Navani; Charles Swanton; Georgios Lyratzopoulos; Ethna McFerran; Mark Lawler; Richard Houlston; Clare Turnbull Journal: Lancet Oncol Date: 2020-07-20 Impact factor: 41.316
Authors: Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen Journal: Eur Urol Date: 2020-05-03 Impact factor: 20.096
Authors: Arnav Srivastava; Hiren V Patel; Sinae Kim; Brian Shinder; Joshua Sterling; Alexandra L Tabakin; Charles F Polotti; Biren Saraiya; Tina Mayer; Isaac Y Kim; Saum Ghodoussipour; Hiten D Patel; Thomas L Jang; Eric A Singer Journal: Urol Oncol Date: 2020-10-20 Impact factor: 3.498
Authors: Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore Journal: Clin Oncol Res Date: 2020-06-26